Compare ASRV & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | NXTC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 46.6M |
| IPO Year | N/A | 2019 |
| Metric | ASRV | NXTC |
|---|---|---|
| Price | $3.15 | $13.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 15.9K | ★ 38.8K |
| Earning Date | 01-20-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $53,488,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.54 | ★ N/A |
| Revenue Growth | ★ 17.45 | N/A |
| 52 Week Low | $2.03 | $2.69 |
| 52 Week High | $3.42 | $15.74 |
| Indicator | ASRV | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 60.28 |
| Support Level | $3.12 | $12.99 |
| Resistance Level | $3.34 | $14.65 |
| Average True Range (ATR) | 0.12 | 1.00 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 74.26 | 78.55 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.